A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Managed Access Programs for INC424, Ruxolitinib
- Status
- AVAILABLE
- Phase
- N/A
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib in Thrombocythemia and Polycythemia Vera
- Status
- RECRUITING
- Phase
- PHASE2
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
- Status
- TERMINATED
- Phase
- PHASE3
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
- Status
- TERMINATED
- Phase
- PHASE3
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
- Status
- TERMINATED
- Phase
- PHASE2
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
- Status
- COMPLETED
- Phase
- PHASE3
Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
- Status
- COMPLETED
- Phase
- PHASE2
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE1